Jennifer Riley - Jan 1, 2025 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Chief Strategy Officer
Signature
/s/ Donald R. Reynolds, by Power of Attorney
Stock symbol
AVTX
Transactions as of
Jan 1, 2025
Transactions value $
$0
Form type
4
Date filed
1/3/2025, 04:06 PM
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Stock Option (Right to Buy) Award $0 +150K $0.00 150K Jan 1, 2025 Common Stock 150K $7.43 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the Option Shares vest on January 1, 2026 and the remainder of the Option Shares will vest in equal monthly installments over the following three (3) years, provided that Optionee remains an employee of the Company on each such vesting date.